Table 5

Comparison of the three treated groups with GERD

Melatonin

Omeprazole

Melatonin and Omeprazole

P value


P1

P2

P3


A)Symptoms:

Heart burn:

control

0

0

0

pretreatment:

yes

7

7

8

duration (months)

1.3 ± 0.4

1.2 ± 0.3

1.4 ± 0.4

4 weeks

8 weeks

3(57.1%)

2(71.4%)

1(87.5%)

0(100%)

0(100%)

0(100%)


Epigastric pain:

-control

0

0

0

pretreatment:

yes

6

6

6

duration (months)

1.4 ± 0.5

1.3 ± 0.4

1.3 ± 0.4

4 weeks

3(50%)

2(66.7%)

1(83.3%)

8 weeks

1(83%)

0(100%)

0(100%)


B) LES Study:

P1

P2

P3

1-LES pressure(mmHg)

control

22.8 ± 1.3

22.8 ± 1.3

22.8 ± 1.3

0.9

0.9

0.9

pretreatment:

10 ± 1.58

10.5 ± 2.86

10.3 ± 1.68

0.65

0.7

0.86

4 weeks

14.5 ± 1.58

10.4 ± 4.05

14.5 ± 1.26

0.006

0.468

0.002

8 weeks

20.2 ± 1.56

10.5 ± 2.85

20.5 ± 1.22

0.000

0.68

0.000


2-Residual pressure (mmHg)

P1

P2

P3

- control

0.4 ± 0.01

0.4 ± 0.01

0.4 ± 0.01

1.0

1.0

1.0

pretreatment:

0.012 ± 0.52

0.1 ± 0.064

0.012 ± 0.44

0.578

1.00

0.556

4 weeks

0.2 ± 0.016

0.2 ± 0.15

0.21 ± 0.016

1.00

0.198

0.198

8 weeks

0.32 ± 0.013

0.1 ± 0.07

0.33 ± 0.016

0.000

0.08

0.000


3-Relaxation duration (seconds)

P1

P2

P3

control

5.0 ± 0.1

5.0 ± 0.1

5.0 ± 0.1

1.0

1.0

1.0

pretreatment::

6.8 ± 0.12

6.5 ± 2.74

6.8 ± 0.16

0.747

1.000

0.747

4 weeks

5.9 ± 0.16

6.3 ± 2.7

5.8 ± 0.13

0.662

0.153

0.585

8 weeks

5.3 ± 0.12

6.3 ± 2.65

5.2 ± 0.12

0.747

0.102

0.059


4-Relaxation %

P1

P2

P3

control

100 ± 0.00

100 ± 0.00

100 ± 0.00

1.0

1.0

1.0

pretreatment:

86 ± 0.87

87.2 ± 0.17

85 ± 1.58

0.12

0.116

0.14

4 weeks

90 ± 0.86

87.3 ± 0.25

90 ± 1.23

0.1

1.000

0.1

8 weeks

100 ± 0.00

87.1 ± 0.1

100 ± 0.00

0.01

1.00

0.01


C) PH (at 5 cm above the LES):

P1

P2

P3

control:

7.8 ± 0.4

7.8 ± 0.4

7.8 ± 0.4

1.0

1.0

1.0

pretreatment:

2.3 ± 0.36

2.1 ± 0.38

1.98 ± 0.37

0.1

0.1

0.1

4 weeks

5.2 ± 0.5

5.9 ± 0.48

6.1 ± 0.55

0.008

0.002

0.09

8 weeks

6.7 ± 0.65

7.2 ± 0.32

7.5 ± 0.31

0.01

0.008

0.1


D) BAO(mmol/h)

P1

P2

P3

- control:

2.6 ± 0.6

2.6 ± 0.6

2.6 ± 0.6

1.0

1.0

1.0

pretreatment:

24.7 ± 0.5

25.1 ± 0.6

24.9 ± 0.7

0.1

0.1

0.1

4 weeks

20.1 ± 0.4

17.2 ± 0.7

15.8 ± 0.9

0.008

0.002

0.09

- 8 weeks

16.6 ± 0.6

11.5 ± 0.6

10.2 ± 0.9

0.01

0.008

0.1


    E) Serum Gastrin(pg/ml)

P1

P2

P3

control:

41.8 ± 7.1

41.8 ± 7.1

41.8 ± 7.1

1.0

1.0

1.0

pretreatment:

22.1 ± 4.2

21.5 ± 4.6

21.9 ± 4.7

0.1

0.1

0.1

4 weeks

27.2 ± 2.3

32.1 ± 2.1

33.6 ± 2.7

0.008

0.002

0.09

- 8 weeks

32.3 ± 2.1

35.9 ± 1.8

36.8 ± 2.1

0.01

0.008

0.1


D) Melatonin level at day time (pg/ml):

P1

P2

P3

control

36.1 ± 2.3

36.1 ± 2.3

36.1 ± 2.3

1.0

1.0

1.0

pretreatment:

18.2 ± 5.54

18.5 ± 3.75

18.3 ± 3.8

0.1

0.665

0.472

4 weeks

28.26 ± 2.26

19.2 ± 3.47

28.83 ± 1.82

0.000

0.55

0.000

8 weeks

34.5 ± .35

17.9 ± 3.72

34.5 ± 2.35

0.000

1.00

0.000


P1: group III versus group II

P2: group IV versus group II

P3: group IV versus group III

Kandil et al. BMC Gastroenterology 2010 10:7   doi:10.1186/1471-230X-10-7

Open Data